Logo image of NERV

MINERVA NEUROSCIENCES INC (NERV) Stock Overview

USA - NASDAQ:NERV - US6033802058 - Common Stock

2.11 USD
0 (0%)
Last: 10/3/2025, 10:07:41 AM

NERV Key Statistics, Chart & Performance

Key Statistics
52 Week High2.83
52 Week Low1.15
Market Cap14.75M
Shares6.99M
Float5.44M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.03
PEN/A
Fwd PEN/A
Earnings (Next)11-03 2025-11-03
IPO06-25 2014-06-25
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


NERV short term performance overview.The bars show the price performance of NERV in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40

NERV long term performance overview.The bars show the price performance of NERV in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of NERV is 2.11 USD. In the past month the price decreased by -8.84%. In the past year, price decreased by -19.71%.

MINERVA NEUROSCIENCES INC / NERV Daily stock chart

NERV Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 22.33 417.76B
AMGN AMGEN INC 13.65 160.27B
GILD GILEAD SCIENCES INC 14.33 137.59B
VRTX VERTEX PHARMACEUTICALS INC 24.13 104.82B
REGN REGENERON PHARMACEUTICALS 13.29 64.28B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.99B
ARGX ARGENX SE - ADR 85.54 48.53B
ONC BEONE MEDICINES LTD-ADR 5.93 40.31B
INSM INSMED INC N/A 32.51B
BNTX BIONTECH SE-ADR N/A 25.24B
BIIB BIOGEN INC 9.85 23.11B
NTRA NATERA INC N/A 22.32B

About NERV

Company Profile

NERV logo image Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2014-06-25. The firm is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.

Company Info

MINERVA NEUROSCIENCES INC

1601 Trapelo Road, Suite 284

Waltham MASSACHUSETTS 02451 US

CEO: Remy Luthringer

Employees: 8

NERV Company Website

NERV Investor Relations

Phone: 16176007373

MINERVA NEUROSCIENCES INC / NERV FAQ

What is the stock price of MINERVA NEUROSCIENCES INC today?

The current stock price of NERV is 2.11 USD.


What is the ticker symbol for MINERVA NEUROSCIENCES INC stock?

The exchange symbol of MINERVA NEUROSCIENCES INC is NERV and it is listed on the Nasdaq exchange.


On which exchange is NERV stock listed?

NERV stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for MINERVA NEUROSCIENCES INC stock?

6 analysts have analysed NERV and the average price target is 5.1 USD. This implies a price increase of 141.71% is expected in the next year compared to the current price of 2.11. Check the MINERVA NEUROSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is MINERVA NEUROSCIENCES INC worth?

MINERVA NEUROSCIENCES INC (NERV) has a market capitalization of 14.75M USD. This makes NERV a Nano Cap stock.


How many employees does MINERVA NEUROSCIENCES INC have?

MINERVA NEUROSCIENCES INC (NERV) currently has 8 employees.


What are the support and resistance levels for MINERVA NEUROSCIENCES INC (NERV) stock?

MINERVA NEUROSCIENCES INC (NERV) has a support level at 2.03 and a resistance level at 2.11. Check the full technical report for a detailed analysis of NERV support and resistance levels.


Should I buy MINERVA NEUROSCIENCES INC (NERV) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does MINERVA NEUROSCIENCES INC (NERV) stock pay dividends?

NERV does not pay a dividend.


When does MINERVA NEUROSCIENCES INC (NERV) report earnings?

MINERVA NEUROSCIENCES INC (NERV) will report earnings on 2025-11-03.


What is the Price/Earnings (PE) ratio of MINERVA NEUROSCIENCES INC (NERV)?

MINERVA NEUROSCIENCES INC (NERV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.03).


What is the Short Interest ratio of MINERVA NEUROSCIENCES INC (NERV) stock?

The outstanding short interest for MINERVA NEUROSCIENCES INC (NERV) is 0.75% of its float. Check the ownership tab for more information on the NERV short interest.


NERV Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to NERV. When comparing the yearly performance of all stocks, NERV turns out to be only a medium performer in the overall market: it outperformed 52.42% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

NERV Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to NERV. NERV may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NERV Financial Highlights

Over the last trailing twelve months NERV reported a non-GAAP Earnings per Share(EPS) of -2.03. The EPS increased by 56.25% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA 36.92%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%60.55%
Sales Q2Q%N/A
EPS 1Y (TTM)56.25%
Revenue 1Y (TTM)N/A

NERV Forecast & Estimates

6 analysts have analysed NERV and the average price target is 5.1 USD. This implies a price increase of 141.71% is expected in the next year compared to the current price of 2.11.


Analysts
Analysts43.33
Price Target5.1 (141.71%)
EPS Next Y17.66%
Revenue Next YearN/A

NERV Ownership

Ownership
Inst Owners27.99%
Ins Owners4.02%
Short Float %0.75%
Short Ratio1.52